NASDAQ: REPLReplimune Group Inc Stock
$6.42+0.27 (+4.39%)
Updated Apr 26, 2024
REPL Price
$6.42
Fair Value Price
$1.47
Market Cap
$394.11M
52 Week Low
$5.86
52 Week High
$24.81
P/E
-2.03x
P/B
0.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$209.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
-$172M
Beta
1.24
Next Earnings
May 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A
REPL Overview
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how REPL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
REPL ($6.42) is overvalued by 335.42% relative to our estimate of its Fair Value price of $1.47 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
REPL ($6.42) is not significantly undervalued (335.42%) relative to our estimate of its Fair Value price of $1.47 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
REPL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more REPL due diligence checks available for Premium users.
Be the first to know about important REPL news, forecast changes, insider trades & much more!
REPL News
Valuation
REPL fair value
Fair Value of REPL stock based on Discounted Cash Flow (DCF)
Price
$6.42
Fair Value
$1.47
Overvalued by
335.42%
REPL ($6.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
REPL ($6.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
REPL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
REPL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.03x
Industry
14.88x
Market
41.14x
REPL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.93x
Industry
5.85x
REPL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
REPL's financial health
Profit margin
Revenue
$0.0
Net Income
-$51.1M
Profit Margin
0%
REPL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$532.9M
Liabilities
$111.4M
Debt to equity
0.26
REPL's short-term assets ($479.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REPL's short-term assets ($479.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REPL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
REPL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$47.1M
Investing
$54.0M
Financing
$14.9M
REPL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
REPL vs Biotech Stocks
Replimune Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.